HCV Protease

Shop By

Items 1-50 of 68

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. HCV Nucleoside Inhibitor

    PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor.
  2. HCV replication Inhibitor

    Anguizole is a small molecule inhibits HCV replication and alters NS4B's subcellular distribution.
  3. Hepatitis C virus NS3/4a protease inhibitor

    Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.
  4. HCV NS3/4A protease inhibitor

    Danoprevir is a potent inhibitor of the HCV NS3/4A serine protease.
  5. HCV Polymerase Inhibitor

    VCH-759 is a non-nucleoside inhibitor of HCV RNA-dependent polymerase with sub-micromolar IC50 values versus genotype 1a/1b replicons.
  6. HCV NS3 protease Inhibitor

    Ciluprevir is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease.
  7. HCV NS3-4A protease inhibitor

    Telaprevir (VX-950) is known as protease inhibitors that inhibits the hepatitis C virus NS3.4A serine protease.
  8. NS3 protease inhibitor

    Asunaprevir is an inhibitor of the viral enzyme serine protease NS3.
  9. HCV Nucleotide Inhibitor

    PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM).
  10. NS5A inhibitor

    Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein
  11. NS5A inhibitor

    BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
  12. HCV NS5A inhibitor

    BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
  13. HCV Protease Inhibitor

    Boceprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1.
  14. HCV Protease inhibitor

    VX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
  15. ICN1229, ICN-1229, ICN 1229

    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.
  16. type 1 (SR-BI) inhibitor

    BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.
  17. HCV Protease Inhibitor

    MK-2748 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It demonstrates broad-spectrum antiviral activity across all genotypes (gt1a-gt6) with nanomolar potency (IC₅₀ < 0.115 nM), including strong efficacy against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 is valuable for research on HCV infection and contributes to the understanding of antiviral mechanisms and treatment strategies.
  18. HCV Protease Inhibitor

    AL-611 is an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, demonstrating potent activity with an EC50 value of 5 nM. This compound plays a critical role in antiviral research, particularly in the development of therapeutic strategies against HCV infections. Its effectiveness in inhibiting HCV replication makes it a valuable tool for studies focused on viral RNA synthesis and enzyme interactions.
  19. HCV Protease Inhibitor

    GSK2818713 is a selective Hepatitis C virus (HCV) protease inhibitor that disrupts the replication complex associated with the NS5A protein. This compound exhibits potent anti-HCV activity, making it a valuable tool for studying the replication and life cycle of the virus. GSK2818713 is applicable in research focused on developing therapeutic strategies against Hepatitis C.
  20. HCV Protease Inhibitor

    BI-1230 is a potent inhibitor of the HCV NS3 protease, exhibiting nanomolar activity in blocking viral replication. It demonstrates high selectivity against other serine and cysteine proteases, making it a valuable tool for studying hepatitis C virus infection mechanisms. Additionally, BI-1230 shows favorable pharmacokinetic properties, supporting its potential use in drug development and research applications related to antiviral therapy.
  21. HCV Protease Inhibitor

    MK-6169 is a potent hepatitis C virus (HCV) protease inhibitor that targets the viral NS5A protein. It exhibits broad-spectrum activity against various HCV genotypes, making it a valuable tool for research on antiviral therapies in hepatitis C. This compound is useful for exploring the mechanisms of HCV replication and potential treatment strategies in pharmaceutical development.
  22. HCV Protease Inhibitor

    Isoeuphorbetin is a dimeric coumarin that acts as a potent inhibitor of HCV protease, demonstrated by an IC50 value of 3.63 µg/mL. This compound has significant potential in antiviral research, particularly in the development of therapeutics targeting hepatitis C virus infection. Its ability to effectively block viral protease activity makes it a valuable tool for studying HCV biology and drug discovery.
  23. HCV Protease Inhibitor

    Ac-D-DGla-LI-Cha-C is a potent inhibitor of the hepatitis C virus (HCV) protease, effectively disrupting viral replication. This peptide is instrumental in studying various biological processes and diseases, including cancer, autoimmune disorders, fibrotic conditions, inflammatory responses, neurodegenerative diseases, infectious diseases, lung and cardiovascular disorders, as well as metabolic diseases. Its targeted action on HCV protease makes it a valuable tool for research in virology and therapeutic development.
  24. HCV NS5B polymerase inhibitor

    VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
  25. HCV Polymerase Inhibitor

    Setrobuvir (ANA-598) is a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase
  26. alpha-glucosidase I inhibitor

    Celgosivir is an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
  27. Polymerase inhibitor

    Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).
  28. NS3 protease inhibitor

    Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM)
  29. HCV Polymerase Inhibitor

    HCV-796 is a selectively inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.
  30. HCV RNA polymerase inhibitor

    PSI-6206 is the deaminated derivative of PSI-6130, which is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic HCV reolicon system.
  31. HCV NS5B polymerase inhibitor

    Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.
  32. HCV replication inhibitor

    R-1479 is a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM).
  33. HCV NS3/4A protease inhibitor

    Simeprevir is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).
  34. NS5B polymerase inhibitor

    Tegobuvir (GS-9190 is a non-nucleoside NS5B polymerase inhibitor.
  35. HCV NS3/4A protease inhibitor

    Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
  36. HCV NS3/4A protease inhibitor

    Voxilaprevir (GS-9857) is a fluorinated macrocyclic hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms. GS-9857 improves coverage against commonly encountered NS3 resistance-associated variants (RAVs).
  37. HCV NS5B polymerase inhibitor

    Deleobuvir (BI207127) was a non-nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C

  38. HCV NS3 inhibitor

    GS-9451 is a potent macrocyclic HCV NS3 PI that achieved a median maximal change in HCV RNA of 3.6 log10 IU/mL (range, -4.7 log10 to -3.1 log10 IU/mL) following 3-day monotherapy in treatment-nave patients with HCV genotype 1 infection during phase I.
  39. HCV NS3/4a inhibitor

    MK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
  40. nucleotide analog HCV inhibitor

    PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of HCV.
  41. HCV NS5A inhibitor

    MK 8742, also known as Elbasvir, is a HCV NS5A inhibitor, which is an all-oral, interferon-free regimen for the treatment of HCV infection.
  42. HCV NS3/4A protease inhibitor

    GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected with HCV genotype 1 (GT 1).
  43. HCV Protease Inhibitor

    Faldaprevir is a hepatitis C virus protease inhibitor.
  44. HCV NS5A inhibitor

    Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor.
  45. HCV NS5A inhibitor

    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
  46. HCV NS3/4A inhibitor

    Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively.
  47. HCV NS5A inhibitor

    Ledipasvir acetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  48. NS5A inhibitor

    Elbasvir is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600?pmol/L, based on genotype.
  49. HCV NS3/4A protease inhibitor

    Glecaprevir, also known as ABT-493 and A-1282576, is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.
  50. HCV RNA replication inhibitor

    PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

Items 1-50 of 68

Page
per page
Set Descending Direction